Who Owns Tactile Medical Company?

Tactile Medical Bundle

Get Full Bundle:

	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10
	SWOT	$15	$10

TOTAL:

ADD TO CART

Who controls Tactile Medical?

A 2016 Nasdaq IPO transformed Tactile Medical from founder-led private ownership into a broadly held public medtech company, increasing institutional scrutiny and market oversight. The firm, founded in 1995, focuses on at-home pneumatic compression for lymphedema and chronic venous insufficiency.

Today the company is a single-class public issuer with significant institutional holders, material insider alignment, and growing revenue and profitability; ownership mixes founders, executives, mutual funds, and ETFs. See Tactile Medical Porter's Five Forces Analysis for competitive context.

Tactile Systems Technology was co-founded in the mid-1990s by clinician-entrepreneurs led by Gerald R. Mattys and a small group of medical device operators and clinicians; early ownership was concentrated with founders and key employees, supported by local angel and friends-and-family seed capital.

Founding Team

Gerald R. Mattys emerged as a long-time CEO; founders collectively held a majority stake in the earliest cap table.

Early Capital

Seed funding came from Minnesota-based medical device backers and local angels, with friends-and-family notes later converting to equity.

Equity Terms

Standard medtech vesting applied: four-year schedules with one-year cliffs for founders and early hires.

Cap Table Stabilizers

Early buy-sell provisions and right-of-first-refusal clauses were used to lock in cap table stability pre-revenue.

Option Pools

Founders reserved option pools for key hires; option grants increased as clinical and reimbursement traction grew, modestly diluting founders.

Transition to Institutional Rounds

Friends-and-family and angel notes converted into common and preferred stock ahead of institutional rounds and broader investor interest.

Early ownership practices and cap table mechanics set the stage for later institutional investment and the public ownership data now visible in SEC filings; see a short company overview in Brief History of Tactile Medical.

Key Early Ownership Facts

Founders and early employees maintained majority control initially while preparing for outside investment and clinical scaling.

• Founders collectively held the majority of equity in inception, with option pools reserved for hires.
• Vesting terms were typical: four-year schedules with one-year cliffs.
• Seed capital from angels and Minnesota device backers converted into preferred/common equity before institutional rounds.
• Early legal protections included buy-sell provisions and ROFRs to preserve ownership stability pre-revenue.

Tactile Medical SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

Key inflection points shaping Tactile Medical ownership include institutional venture capital in the 2000s and the June 2016 Nasdaq IPO (ticker: TCMD), which shifted equity toward public institutions and enabled expansion of sales and clinical programs.

By 2024–2025 the shareholder mix shows U.S. index funds and healthcare-focused active managers as leading holders, alongside insiders; SEC filings indicate insiders hold a combined mid-to-high single-digit percent, with the remainder widely held by institutions and retail, and the top 10 holders typically include passive index complexes and healthcare specialists.

Ownership Snapshot and Governance Impact

Tactile Medical ownership shifted from VC concentration to a broadly held public register dominated by institutional investors and modest insider stakes, driving governance and strategy toward profitability and payer engagement.

• IPO (June 2016) raised growth capital and diluted private stakes
• Top 10 holders typically include Vanguard and BlackRock plus healthcare active managers
• Insiders hold mid-to-high single-digit percent collectively per recent SEC filings
• No single controlling shareholder; majority-independent board and focus on margins

For further context on strategy and market positioning tied to ownership trends, see Marketing Strategy of Tactile Medical.

Tactile Medical PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

The current board of directors of Tactile Medical comprises a majority of independent directors, including experienced medtech operators and reimbursement experts; the CEO also serves as a director. The company maintains a one-share-one-vote structure with no dual‑class shares, golden share, or controlling‑shareholder appointees.

Voting power is proportional to shareholdings under the single class common stock framework; large passive funds and healthcare‑focused active managers exert influence through proxy voting but hold no formal super‑control. From 2022 through mid‑2025, proxy activity centered on executive compensation and governance, with say‑on‑pay votes and director re‑elections passing by wide margins consistent with mid‑cap medtech peers.

Board composition and voting dynamics

One‑share‑one‑vote common stock; majority independent board and independent committee chairs. No dual‑class stock or golden share; no controlling shareholder appointees.

• Voting power proportional to holdings; institutional investors drive proxy outcomes
• No successful activist campaigns or proxy battles reported in 2022–2025
• Say‑on‑pay and director votes typically pass with broad support
• Investor relations filings show dispersed ownership among index funds and healthcare specialists

For context on market positioning and shareholder outreach, see Target Market of Tactile Medical

Tactile Medical Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

From 2021–2024 Tactile Medical ownership shifted toward greater institutional concentration as float maturation and improved liquidity attracted healthcare specialists and passive index trackers; insiders continued routine 10b5-1 sales but no founder control blocks emerged, and management prioritized profitability and reimbursement quality.

Analysts cited margin expansion and improved cash flow conversion as key drivers for sustained institutional support, with potential opportunistic financing only if growth investments required, and no public indications of imminent capital structure changes beyond ordinary-course equity compensation.

Institutional concentration

Large passive managers and healthcare specialists increased stakes as liquidity improved; institutional investors became primary holders of tradable float.

Insider activity

Insider transactions were mostly routine 10b5-1 plans tied to vesting; executives retained meaningful alignment with shareholders.

Capital structure stance

No dual-class shares adopted and no material recapitalizations announced through mid-2025; ordinary equity comp and opportunistic financing remain the likely levers.

Governance emphasis

Industry consolidation among large managers increased focus on governance, compliance, and payer-driven revenue quality as determinants of investor support.

For a broader market and competitor context and a list of factors influencing who owns Tactile Medical and how to find major shareholders, see Competitors Landscape of Tactile Medical

Tactile Medical Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔